ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Income Before Tax

Profit after all operating and non-operating items but before income tax.

ImageneBio IncNASDAQ: IMA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$10.61M, compared with -$8.59M a year earlier. Trailing-twelve-month income before tax was -$45.4M.

Context

  • Income before tax amounted to 5712.4% of revenue in FY2025, up 4667.9 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$10.61M or moves back toward the trailing-twelve-month quarterly average of -$11.35M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.61M-47.7% QoQ
Last fiscal yearDec 2025
-$45.7M-25.0% YoY
LTMMar 2026
-$45.4M-9.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.5%——
1 year-25.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(45.7M) USD
Year-over-year change
-25.0%

Income Before Tax vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.3% is the 6th highest of 9, against a peer median of +2.5%.
IMA Competitors
Income Before Tax for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24.17M USD+3.2%—339.3%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.23M USD-45.6%——
IFRXInflaRx N.V.LTM Mar 2026-€42.81M EUR+1.7%—145945.5%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.1M USD+38.9%——
IMAImageneBio IncLTM Mar 2026-$45.4M USD-9.3%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
CNTBConnect Biopharma Holdings LimitedFY2025-$55.28M USD-258.9%—86379.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$87.07M USD-34.3%——
STROSutro Biopharma, Inc.LTM Mar 2026-$153.72M USD+36.7%—154.3%
Peer median (excluding IMA) —+2.5%—4987.4%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.